THE ACTIVATION OF TYPE-1 AND TYPE-2 PLASMINOGEN BY TYPE-I AND TYPE-II TISSUE-PLASMINOGEN ACTIVATOR

被引:38
作者
MORI, K
DWEK, RA
DOWNING, AK
OPDENAKKER, G
RUDD, PM
机构
[1] UNIV OXFORD,INST GLYCOBIOL,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND
[2] CATHOLIC UNIV LEUVEN,REGA INST MED RES,B-3000 LOUVAIN,BELGIUM
关键词
D O I
10.1074/jbc.270.7.3261
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tissue plasminogen activator (tPA) was fractionated using lysine-Sepharose affinity chromatography. Type I, type II, and a minor peak with high affinity for lysine (designated type D) tPA were recovered. In an indirect amidolytic assay involving native human Glu-plasminogem and fibrin, type II tPA showed a 2-fold higher activity than type I. To explore the combinatorial effect of the variable glycosylation status of both tPA and plasminogen, kinetic constants for fibrin-dependent plasminogen activation were determined for combinations of type I, II, and D tPA with type 1 and 2 plasminogen. Within a 4-fold range, the fastest rate was achieved from the combination of type D* (type II + D) tPA and type 2 plasminogen. N-Glycosylation of plasminogen increased the K-m value for activation by all tPA variants; N-glycosylation of type I tPA at Asn(184) decreased the k(cat) (turnover) values for the fibrin-dependent activation of plasminogen over type II tPA, while type D* tPA showed the highest turnover rate, In the presence of fibrinogen fragments, N-glycosylation of plasminogen at site 289 modulates the kinetics of association of enzyme and substrate, while N-glycosylation at site 184 on tPA modulates the turnover rate of the enzyme.
引用
收藏
页码:3261 / 3267
页数:7
相关论文
共 38 条
[1]   FIBRINOLYSIS IN THE ANIMAL ORGANISM [J].
ASTRUP, T ;
PERMIN, PM .
NATURE, 1947, 159 (4046) :681-682
[2]  
BERG DT, 1993, BLOOD, V81, P1312
[3]   MEASUREMENT OF BINDING OF ANTIFIBRINOLYTIC AMINO-ACIDS TO VARIOUS PLASMINOGENS [J].
BROCKWAY, WJ ;
CASTELLINO, FJ .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1972, 151 (01) :194-+
[4]  
COLLEN D, 1991, BLOOD, V78, P3114
[5]   TOWARDS IMPROVED THROMBOLYTIC THERAPY [J].
COLLEN, D .
LANCET, 1993, 342 (8862) :34-36
[6]   PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER [J].
DANO, K ;
ANDREASEN, PA ;
GRONDAHLHANSEN, J ;
KRISTENSEN, P ;
NIELSEN, LS ;
SKRIVER, L .
ADVANCES IN CANCER RESEARCH, 1985, 44 :139-266
[7]   THE INFLUENCE OF THE NATURE OF THE ASPARAGINE 289-LINKED OLIGOSACCHARIDE ON THE ACTIVATION BY UROKINASE AND LYSINE BINDING-PROPERTIES OF NATURAL AND RECOMBINANT HUMAN PLASMINOGENS [J].
DAVIDSON, DJ ;
CASTELLINO, FJ .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (01) :249-254
[8]   CRYSTAL-STRUCTURE OF THE KRINGLE-2 DOMAIN OF TISSUE PLASMINOGEN-ACTIVATOR AT 2.4-A RESOLUTION [J].
DEVOS, AM ;
ULTSCH, MH ;
KELLEY, RF ;
PADMANABHAN, K ;
TULINSKY, A ;
WESTBROOK, ML ;
KOSSIAKOFF, AA .
BIOCHEMISTRY, 1992, 31 (01) :270-279
[9]   NEONATAL PLASMINOGEN DISPLAYS ALTERED CELL-SURFACE BINDING AND ACTIVATION KINETICS - CORRELATION WITH INCREASED GLYCOSYLATION OF THE PROTEIN [J].
EDELBERG, JM ;
ENGHILD, JJ ;
PIZZO, SV ;
GONZALEZGRONOW, M .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (01) :107-112
[10]  
ERINARSSON M, 1985, BIOCHIM BIOPHYS ACTA, V830, P1